US63009J1079
© Globe Newswire
15.12.2025
NBTX
LISTED
NASDAQ
NANOBIOTIX to Join CAC Mid 60 and SBF 120 Indices on Euronext Paris
News Preview
PARIS and CAMBRIDGE, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced that following the annual review of the...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.11.2025
NBTX
LISTED
NASDAQ
Nanobiotix Provides Third Quarter 2025 Operational and Financial Update Along With 2026 Clinical Outlook
News Preview
PARIS and CAMBRIDGE, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, today reported an operational update and financial result...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.11.2025
NBTX
LISTED
NASDAQ
Voting Rights and Shares Capital of the Company
News Preview
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© Globe Newswire
13.11.2025
NBTX
LISTED
NASDAQ
NANOBIOTIX Announces Curadigm Nanoprimer Platform Advancements With Updated Plans for Internal Pipeline Development and External Collaborations
News Preview
PARIS and CAMBRIDGE, Mass., Nov. 13, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced advancements for its next-wave Curadigm Na...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
11.11.2025
NBTX
LISTED
NASDAQ
NANOBIOTIX to Participate in Jefferies London Healthcare Conference
News Preview
PARIS and CAMBRIDGE, Mass., Nov. 11, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in...
Themefolio
Profiler
Peergroup
© Globe Newswire
31.10.2025
NBTX
LISTED
NASDAQ
NANOBIOTIX Announces Strategic Royalty Monetization Agreement With Healthcare Royalty for up to $71 Million and Extends Cash Runway Toward Long-Term Growth
News Preview
PARIS and CAMBRIDGE, Mass., Oct. 31, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced that it has entered into a royalty-based f...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.10.2025
NBTX
LISTED
NASDAQ
NANOBIOTIX Announces Updates to JNJ-1900 (NBTXR3) Clinical Program Following Transfer of Ongoing Phase 3 Head and Neck Cancer Trial Sponsorship and Operational Control
News Preview
PARIS and CAMBRIDGE, Mass., Oct. 24, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced updates to the JNJ-1900 (NBTXR3) clinical...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.10.2025
NBTX
LISTED
NASDAQ
Voting Rights and Shares Capital of the Company
News Preview
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.09.2025
NBTX
LISTED
NASDAQ
NANOBIOTIX Provides Business Update and Reports Half Year 2025 Financial Results
News Preview
PARIS and CAMBRIDGE, Mass., Sept. 30, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, provided an update on operational progress and announced i...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.09.2025
NBTX
LISTED
NASDAQ
NANOBIOTIX Announces Updated Phase 1 Results Continuing to Support JNJ-1900 (NBTXR3) Plus Anti-PD-1 as a Potential New 1L or 2L+ Option in Anti-PD-1 Naïve or Resistant R/M-HNSCC
News Preview
Data presented as a “Top-rated Abstract in Head and Neck Cancer” at the 2025 Annual Meeting of the American Society for Radiation Oncology (ASTRO) on September 29th...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.09.2025
NBTX
LISTED
NASDAQ
NANOBIOTIX Announces New Results From a Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Combination With Immune Checkpoint Inhibitors as a 2L+ Therapy for Patients With Primary Cutaneous Melanoma Resistant to Anti-PD-1
News Preview
Data presented on September 17 at the 2025 Immunorad Conference...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.09.2025
NBTX
LISTED
NASDAQ
Voting Rights and Shares Capital of the Company
News Preview
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
02.09.2025
NBTX
LISTED
NASDAQ
Nanobiotix to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
News Preview
PARIS and CAMBRIDGE, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will partici...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.08.2025
NBTX
LISTED
NASDAQ
Voting Rights and Shares Capital of the Company
News Preview
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.07.2025
NBTX
LISTED
NASDAQ
NANOBIOTIX Announces Regulatory Harmonization and New Composition of Matter Patent Filed for JNJ-1900 (NBTXR3)
News Preview
PARIS and CAMBRIDGE, Mass., July 07, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced two important developments that aim to reinforce the global positi...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.06.2025
NBTX
LISTED
NASDAQ
Voting Rights and Shares Capital of the Company
News Preview
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.05.2025
NBTX
LISTED
NASDAQ
NANOBIOTIX to Participate in the Jefferies Global Healthcare Investor Conference
News Preview
PARIS and CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participa...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.05.2025
NBTX
LISTED
NASDAQ
Nanobiotix Provides First Quarter 2025 Operational and Financial Update
News Preview
PARIS and CAMBRIDGE, Mass., May 21, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today provided an update on operational progress and reporte...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.05.2025
NBTX
LISTED
NASDAQ
Voting Rights and Shares Capital of the Company
News Preview
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.05.2025
NBTX
LISTED
NASDAQ
Nanobiotix to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ
News Preview
PARIS and CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participa...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.05.2025
NBTX
LISTED
NASDAQ
Nanobiotix Announces Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer
News Preview
Data presented at the 2025 Annual Meeting of the European Society of Radiation Oncology...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.04.2025
NBTX
LISTED
NASDAQ
Voting Rights and Shares Capital of the Company
News Preview
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.04.2025
NBTX
LISTED
NASDAQ
NANOBIOTIX Provides Business Update and Reports Full Year 2024 Financial Results
News Preview
Conference call and webcast scheduled for April 3, 2025 at 8:00 A.M. EDT / 2:00 P.M. CEST...
Themefolio
Profiler
Peergroup
© Globe Newswire
31.03.2025
NBTX
LISTED
NASDAQ
NANOBIOTIX to Announce Fourth Quarter and Full Year 2024 Operational and Financial Update on April 2, 2025
News Preview
Conference call and webcast scheduled for Thursday, April 3, 2025, at 8:00 am EDT / 2:00 pm CEST Conference call and webcast scheduled for Thursday, April 3, 2025, at 8:00 am EDT / 2:00 pm CEST...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.03.2025
NBTX
LISTED
NASDAQ
Nanobiotix Announces First Data From the Completed Dose Escalation Part of a Phase 1 Study Evaluating NBTXR3 (JNJ-1900) as a 2L+ Therapy for Patients With Locally Advanced NSCLC
News Preview
PARIS and CAMBRIDGE, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-stage clinical biotechnology company pioneering disruptive, nanotherapeutic approaches to revolutionize treatment outcomes for millions of patients, today announced the first data from the completed dose escalation...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.03.2025
NBTX
LISTED
NASDAQ
NANOBIOTIX Announces Presentation of Data From Two Phase 1 Studies Evaluating JNJ-1900 (NBTXR3) at the European Lung Cancer Conference
News Preview
PARIS and CAMBRIDGE, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced poster presentations fro...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.03.2025
NBTX
LISTED
NASDAQ
NANOBIOTIX Strengthens Financial Position Through Amendment of Global Licensing Agreement for JNJ-1900 (NBTXR3) and Extends Cash Visibility to Mid-2026
News Preview
Conference call and webcast scheduled for March 18, 2025, at 8:30 A.M. EDT / 1:30 P.M. CET Conference call and webcast scheduled for March 18, 2025, at 8:30 A.M. EDT / 1:30 P.M. CET...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.03.2025
NBTX
LISTED
NASDAQ
Voting Rights and Shares Capital of the Company
News Preview
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.02.2025
NBTX
LISTED
NASDAQ
Voting Rights and Shares Capital of the Company
News Preview
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.01.2025
NBTX
LISTED
NASDAQ
Nanobiotix to Participate in Multiple Investor Conferences in February and March 2025
News Preview
PARIS and CAMBRIDGE, Mass., Jan. 29, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will particip...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.01.2025
NBTX
LISTED
NASDAQ
NANOBIOTIX Announces First Patient Dosed in a New Randomized Phase 2 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer
News Preview
PARIS and CAMBRIDGE, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced that the first patient ha...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.01.2025
NBTX
LISTED
NASDAQ
Voting Rights and Shares Capital of the Company
News Preview
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.12.2024
NBTX
LISTED
NASDAQ
NANOBIOTIX to Introduce Vision for Transforming Drug Design and Development with Next Nanotherapeutic Platform on 19 December 2024
News Preview
PARIS and CAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced a virtual event titled "A...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.12.2024
NBTX
LISTED
NASDAQ
Voting Rights and Shares Capital of the Company
News Preview
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.12.2024
NBTX
LISTED
NASDAQ
NANOBIOTIX Announces Completion of Phase 1 Study of NBTXR3 (JNJ-1900) in Pancreatic Cancer
News Preview
PARIS and CAMBRIDGE, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced the completion of the dos...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.11.2024
NBTX
LISTED
NASDAQ
Voting Rights and Shares Capital of the Company
News Preview
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.11.2024
NBTX
LISTED
NASDAQ
NANOBIOTIX Provides Third Quarter 2024 Update and Progress on Nanotherapeutics Platforms
News Preview
PARIS and CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, provided an update on operational progress and reported...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.10.2024
NBTX
LISTED
NASDAQ
Voting Rights and Shares Capital of the Company
News Preview
In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.09.2024
NBTX
LISTED
NASDAQ
NANOBIOTIX Provides Business Update and Reports Half Year 2024 Financial Results
News Preview
PARIS and CAMBRIDGE, Mass., Sept. 18, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, provided an update on operational progress and announce...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.09.2024
NBTX
LISTED
NASDAQ
NANOBIOTIX Announces Two Key Supervisory Board Additions Intended to Further Equip the Company for Sustainable Long-Term Growth
News Preview
PARIS and CAMBRIDGE, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced the nominations of Dr. M...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.09.2024
NBTX
LISTED
NASDAQ
Nanobiotix to Present at H.C. Wainwright 26th Annual Global Investment Conference
News Preview
PARIS and CAMBRIDGE, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced today that Company management will participate in a fireside chat at th...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.08.2024
NBTX
LISTED
NASDAQ
Voting Rights and Shares Capital of the Company
News Preview
In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.07.2024
NBTX
LISTED
NASDAQ
Voting Rights and Shares Capital of the Company
News Preview
In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.06.2024
NBTX
LISTED
NASDAQ
NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024
News Preview
PARIS and CAMBRIDGE, Mass., June 12, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that it will host a virtual KOL (Key Opinion Leader) event Tuesday...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.06.2024
NBTX
LISTED
NASDAQ
Voting Rights and Shares Capital of the Company
News Preview
In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.06.2024
NBTX
LISTED
NASDAQ
Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+ R/M HNSCC Naïve or Resistant to Prior anti-PD-1 Therapy
News Preview
PARIS and CAMBRIDGE, Mass., June 02, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced new data from Study 1100,...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.05.2024
NBTX
LISTED
NASDAQ
NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual Meeting of the American Society for Clinical Oncology Followed by an Investor Conference Call
News Preview
PARIS and CAMBRIDGE, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced the presentation of update...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.05.2024
NBTX
LISTED
NASDAQ
NANOBIOTIX to Present at the Jefferies Global Healthcare Conference
News Preview
PARIS and CAMBRIDGE, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced today that Company management will participate in a fireside chat at the u...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.05.2024
NBTX
LISTED
NASDAQ
NANOBIOTIX Provides First Quarter 2024 Operational and Financial Update
News Preview
PARIS and CAMBRIDGE, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today provided an update on operational progress and reported financial results for...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.05.2024
NBTX
LISTED
NASDAQ
Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term Growth
News Preview
PARIS and CAMBRIDGE, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced updates to its corporate...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.05.2024
NBTX
LISTED
NASDAQ
Voting Rights and Shares Capital of the Company
News Preview
In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.05.2024
NBTX
LISTED
NASDAQ
NANOBIOTIX Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating NBTXR3 for Patients with Stage Three Lung Cancer
News Preview
PARIS and CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced that the U.S. Food and Dru...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
